BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
IPO Year:
Exchange: NASDAQ
Website: biolase.com
LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL
LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced that the Company received a notice from Nasdaq that it has determined to delist the shares of the Company's common stock from The Nasdaq Stock Market. The delisting is a result of failure to satisfy the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) and failure to comply with Nasdaq's $2,500,000 minimum stockholders' equity requirement for continued listing or any of the alternative requirements in Listing Rule 5550(b). Suspension of trading in the Company's common stock on the Nasdaq exchange will be effective at the open of trading on
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re
LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.To access the live call, dial 877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approxi
LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year.2023 Full-Year HighlightsAchieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.Key performance metrics demonstrate continued growth and momentum, including:Record consumable sales, including the introduction of recurring revenue subscriptions.Increased adoption of its industry-leading laser systems.Increased sales con
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.To access the live call, dial 877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay wil
Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.Key features of the Waterlase iPlus Premier Edition include:Modular Software Design: At the heart of the Waterlase
LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas. Dr. Chang lectured on the clinical benefits of using the Waterlase all-tissue dental laser for extractions and im
8-K - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
10-Q - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
S-1 - BIOLASE, INC (0000811240) (Filer)
8-K - BIOLASE, INC (0000811240) (Filer)
SC 13G - BIOLASE, INC (0000811240) (Subject)
SC 13G - BIOLASE, INC (0000811240) (Subject)
SC 13G - BIOLASE, INC (0000811240) (Subject)
SC 13G/A - BIOLASE, INC (0000811240) (Subject)
SC 13G/A - BIOLASE, INC (0000811240) (Subject)
SC 13G/A - BIOLASE, INC (0000811240) (Subject)
SC 13G - BIOLASE, INC (0000811240) (Subject)
SC 13G/A - BIOLASE, INC (0000811240) (Subject)
SC 13G - BIOLASE, INC (0000811240) (Subject)
SC 13G - BIOLASE, INC (0000811240) (Subject)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4/A - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
4 - BIOLASE, INC (0000811240) (Issuer)
LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe
DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re
LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.To access the live call, dial 877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approxi
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.To access the live call, dial 877-270-2148 (U.S.) or +1 412-902-6510 (International) and ask to join the BIOLASE call.A live and archived conference call webcast will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay wil
LAKE FOREST, Calif., Dec. 14, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has been awarded a Top Workplaces 2023 honor by Orange County Register Top Workplaces. The award is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The confidential survey uniquely measures 15 culture drivers that are critical to success, including alignment, execution, and connection. "Earning a Top Workplaces award is a badge of honor for companies, e
LAKE FOREST, Calif., Aug. 2, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it will release second quarter 2023 financial and operating results on Thursday, August 10, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments. To access the live call, dial 888-506-0062 (U.S.) or +1 973-528-0011 (International) and provide the following access code: 679201. A live and archived webcast of the c
LAKE FOREST, Calif., June 5, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of record as of 5:00 p.m. Eastern Time on June 16, 2023. The outstanding shares of Series I Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split and will not be entitled to vote on any other matter, except to the extent r
Educational and Training Programs Introducing Broader Community of Dentists to Experience Industry-Leading Dental Lasers for the First Time LAKE FOREST, Calif., May 11, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Financial Highlights Reported revenue of $10.5 million, the ninth consecutive quarter of year-over-year growthIncreased international laser sales by 22% year over yearRecord quarter in consumable sales, with U.S. consumable sales i
LAKE FOREST, Calif., May 4, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it will release first quarter 2023 financial and operating results on Thursday, May 11, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments. To access the live call, dial 877-545-0523 (U.S.) or +1 973-528-0016 (International) and provide the following access code: 180082. A live and archived webcast of the confer
Colliers Securities resumed coverage of BIOLASE with a rating of Buy and set a new price target of $1.15
Maxim Group reiterated coverage of BIOLASE with a rating of Buy and set a new price target of $2.00 from $1.00 previously
Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.
Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.
FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million. ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million. Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million. Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million. SAB Biotherapeutics (NASDAQ:SABS)
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 60.2% to $0.27 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.2 million. As per the press release, Q4 earnings came out 2 days ago. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 31.21% to $0.98. The market value of their outstanding shares is at $27.7 million. Geovax Labs (NASDAQ:GOVX) shares increased by 24.32% to $1.38. The market value of their outstanding shares is at $3.4 million. Silk Road Medical (NASDAQ:SILK) stock increased by 23.67% to $26.8. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) shares rose 18.91% to $0.19. The market value of their outs
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 63.8% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. As per the news, the Q4 earnings report came out yesterday. Qualigen Therapeutics (NASDAQ:QLGN) stock rose 31.57% to $0.23. The company's market cap stands at $1.4 million. Mustang Bio (NASDAQ:MBIO) shares rose 30.66% to $0.98. The company's market cap stands at $27.6 million. Autonomix Medical (NASDAQ:AMIX) stock rose 25.92% to $1.7. The market value of their outstanding shares is at $32.0 million. Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.9% to $26.85. The market value of their outstanding shares is at $1.
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results. The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-year to $30.73 billion, beating the analyst consensus estimate of $30.40 billion. Adjusted earnings per ADS of $1.40 missed the analyst consensus estimate of $1.41, according to data from Benzinga Pro. Alibaba Group shares tumbled 6.8% to $78.86 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) shares jumped 352.4% to $5.34 as the company reported pricing of $8.19 million
Gainers Delcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out today. Harrow (NASDAQ:HROW) stock rose 32.64% to $16.01. The company's market cap stands at $566.4 million. As per the press release, Q1 earnings came out yesterday. ProKidney (NASDAQ:PROK) shares moved upwards by 26.29% to $3.89. The company's market cap stands at $248.6 million. As per the news, the Q1 earnings report came out 2 days ago. Sunshine Biopharma (NASDAQ:SBFM) stock rose 25.14% to $1.09. The market value of their outstanding shares is at $1.0 million. Pacific Biosciences (NASDAQ:
Benchmark analyst Bruce Jackson reiterates Biolase (NASDAQ:BIOL) with a Speculative Buy and maintains $0.4 price target.
Shares of Alcon Inc. (NYSE:ALC) rose sharply in today's pre-market trading following better-than-expected first-quarter earnings. Alcon posted adjusted earnings of 78 cents per share, beating market expectations of 63 cents per share. The company's quarterly sales came in at $2.444 billion versus estimates of $2.462 billion, according to data from Benzinga Pro. Alcon shares jumped 10.8% to $89.40 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers GameStop Corp. (NYSE:GME) gained 40.2% to $42.70 in pre-market trading after jumping over 74% on Monday. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 39.2% to $0.08